Dow announced the advancement of a series of targeted investment projects totaling approximately US$100 million by the end of 2027 to expand its global specialty silicones manufacturing and innovation capabilities.

The investments will expand Dow’s specialty silicones capabilities across the United States, China and Japan, focusing on advanced silicones and processing capabilities to meet growing global demand in mobility, electronics and health care applications.

Investments include:

• Liquid silicone rubber (LSR) manufacturing expansions in Carrollton (US) and Zhangjiagang (China) expected to come online in 2027, supporting high-performance applications across mobility, electronics and health care.

• Capacity expansions for engineered silicone materials supporting advanced electronics applications, including power electronics, semiconductor packaging, thermal and electrical protection, are scheduled to come online this year in Songjiang (China) and Fukui (Japan), with additional expansions in Auburn (US) and Zhangjiagang (China), expected in 2027, strengthening Dow’s specialty materials innovation and manufacturing backbone.

• Expanded Cooling Science Labs in Shanghai (China) earlier this year, and in Midland (US) in June, supporting faster customer innovation for the development and scale-up of next-generation thermal management solutions.

Why Dow is investing in specialty silicones capabilities

Demand for specialty silicones continues to grow across mobility, electronics and medical applications, where product performance, supply reliability and technical capabilities are critical.

Dow’s investments are designed to support these trends through regional, local-for-local manufacturing that aligns capacity with customer demand.

In mobility and electronics applications, the expanded capabilities support growing demand for high performance, reliable silicone solutions used in mobility intelligence modules, data centers and microelectronics, energy electronics, consumer electronics components, and advanced safety systems.

In medical applications, the expanded footprint reinforces Dow’s value proposition of end-to-end local supply, an increasingly important requirement for regulated and mission-critical products.

Collectively across these applications, local manufacturing and technical support enhance Dow’s ability to deliver consistent quality, accelerate commercialization, and provide customers globally with manufacturing scale close to key demand centers.